Price Chart

Profile

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
URL https://www.myriad.com
Investor Relations URL https://investor.myriad.com/
HQ State/Province Utah
Sector Healthcare
Industry Diagnostics & Research
Equity Style Small Cap/Growth
Next Earnings Release Feb. 28, 2024 (est.)
Last Earnings Release Nov. 06, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
URL https://www.myriad.com
Investor Relations URL https://investor.myriad.com/
HQ State/Province Utah
Sector Healthcare
Industry Diagnostics & Research
Equity Style Small Cap/Growth
Next Earnings Release Feb. 28, 2024 (est.)
Last Earnings Release Nov. 06, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A